āĻšā§āĻŽDBVT âĸ NASDAQ
add
DBV Technologies SA - ADR
ā§§ā§¯.ā§Ēā§Ģ$
āĻāĻŖā§āĻāĻž āĻĒāĻ°ā§:(ā§Ļ.ā§Ļā§Ļ%)ā§Ļ.ā§Ļā§Ļ
ā§§ā§¯.ā§Ēā§Ģ$
āĻŦāĻ¨ā§āĻ§ āĻāĻā§: ā§§ā§¯ āĻŽāĻžāĻ°ā§āĻ, ā§Ē:ā§Ļā§Ļ:ā§¨ā§§ PM GMT -ā§Ē · USD · NASDAQ · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻ¸ā§āĻāĻāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻ¤āĻžāĻ˛āĻŋāĻāĻžāĻā§āĻā§āĻ¤ āĻ¸āĻŋāĻāĻŋāĻāĻ°āĻŋāĻāĻŋ
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§¯.ā§Ēā§Ģ$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§§ā§Ž.ā§¯ā§Š$ - ā§§ā§¯.ā§Ģā§Ž$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§Š.ā§¯ā§§$ - ā§¨ā§Ŧ.ā§§ā§¯$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§§ā§Ļā§Ž.ā§Ļā§Â āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§¨.ā§ā§§Â āĻ˛āĻž
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
-
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
-
āĻāĻŦāĻ°ā§ āĻ°ā§ā§āĻā§
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (EUR) | ā§¨ā§Ļā§§ā§Žinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§§.ā§§ā§¨Â āĻā§ | ā§§ā§Ŧ.ā§Ģā§§% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§§ā§.ā§ā§Ē āĻā§ | ā§§ā§Ē.ā§ā§Ŧ% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§ā§Ŧ.ā§Ŧā§§Â āĻā§ | -ā§§ā§¨.ā§Ēā§Ģ% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | -ā§§.ā§Ēā§ŽÂ āĻšāĻž | ā§Š.ā§Ēā§¯% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | -ā§Ģā§.ā§Ēā§Ļ | -ā§Šā§Žā§Ļ.ā§ā§Ē% |
EBITDA | -ā§§ā§Ŧ.ā§¨ā§Ļ āĻā§ | -ā§§ā§Š.ā§¯ā§Ē% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | -ā§Ļ.ā§Ļā§§% | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (EUR) | ā§¨ā§Ļā§§ā§Žinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§§ā§¨.ā§¨ā§ŽÂ āĻā§ | -ā§§ā§Ļ.ā§¯ā§Ŧ% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§§ā§.ā§§ā§Â āĻā§ | -ā§Š.ā§Ēā§§% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Ģ.ā§Ļā§Ģ āĻā§ | ā§Ģ.ā§Šā§¯% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§ā§¨.ā§§ā§ŠÂ āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§Š.ā§Ļā§§Â āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§Ē.ā§Žā§Š | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§Ģā§¯.ā§Ēā§Ē% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | -ā§Žā§Ļ.ā§Ģā§¯% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (EUR) | ā§¨ā§Ļā§§ā§Žinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§ā§Ŧ.ā§Ŧā§§Â āĻā§ | -ā§§ā§¨.ā§Ēā§Ģ% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | -ā§§ā§Š.ā§Ŧā§Ŧ āĻā§ | -ā§§ā§¯.ā§Ģā§§% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§Žā§Ŧ.ā§Ēā§§Â āĻ˛āĻž | -ā§§ā§Ļ.ā§Šā§Ļ% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§§ā§Š.ā§Ļā§Â āĻā§ | ā§Ēā§Ģ,ā§Ģā§¯ā§Ļ.ā§¯ā§§% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§§.ā§Ģā§§Â āĻā§ | ā§Žā§.ā§¨ā§Ŧ% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | -ā§.ā§¨ā§Ŧ āĻā§ | -ā§§ā§Ž.ā§Ēā§§% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
āĻ¸āĻŋāĻāĻ
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§¨ā§¯ āĻŽāĻžāĻ°ā§āĻ, ā§¨ā§Ļā§Ļā§¨
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§§ā§§ā§
